Efficacy of radiation countermeasures depends on radiation quality

Radiat Res. 2012 May;177(5):663-75. doi: 10.1667/rr2783.1. Epub 2012 Apr 3.

Abstract

The detonation of a nuclear weapon or a nuclear accident represent possible events with significant exposure to mixed neutron/γ-radiation fields. Although radiation countermeasures generally have been studied in subjects exposed to pure photons (γ or X rays), the mechanisms of injury of these low linear energy transfer (LET) radiations are different from those of high-LET radiation such as neutrons, and these differences may affect countermeasure efficacy. We compared 30-day survival in mice after varying doses of pure γ and mixed neutron/γ (mixed field) radiation (MF, Dn/Dt = 0.65), and also examined peripheral blood cells, bone marrow cell reconstitution, and cytokine expression. Mixed-field-irradiated mice displayed prolonged defects in T-cell populations compared to mice irradiated with pure γ photons. In mouse survival assays, the growth factor granulocyte colony-stimulating factor (G-CSF) was effective as a (post-irradiation) mitigator against both γ-photons and mixed-field radiation, while the thrombopoietin (TPO) mimetic ALXN4100TPO was effective only against γ irradiation. The results indicate that radiation countermeasures should be tested against radiation qualities appropriate for specific scenarios before inclusion in response plans.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bone Marrow / drug effects
  • Bone Marrow / pathology
  • Bone Marrow / radiation effects
  • Bone Marrow Diseases / blood
  • Bone Marrow Diseases / etiology
  • Bone Marrow Diseases / immunology
  • Bone Marrow Diseases / prevention & control*
  • Cytokines / blood
  • Drug Evaluation, Preclinical
  • Filgrastim
  • Gamma Rays / adverse effects*
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoiesis / drug effects
  • Hematopoiesis / radiation effects
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / pathology
  • Hematopoietic Stem Cells / radiation effects
  • Lymphocyte Count
  • Mice
  • Neutrons / adverse effects*
  • Radiation Injuries, Experimental / blood
  • Radiation Injuries, Experimental / etiology
  • Radiation Injuries, Experimental / immunology
  • Radiation Injuries, Experimental / prevention & control*
  • Radiation-Protective Agents / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Spleen / drug effects
  • Spleen / pathology
  • Spleen / radiation effects
  • T-Lymphocytes / radiation effects
  • Thrombopoietin / therapeutic use*

Substances

  • ALXN4100TPO
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Radiation-Protective Agents
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Thrombopoietin
  • Filgrastim